Il-17 receptor a is required for il-17c biology
AssigneeAmgen Inc.
InventorsAlison L. Budelsky, Jennifer E. Towne, Yu Zhang, Lori Siegel, Antony Symons
Life of this patent
Estimating the term…
Abstract
The present invention relates to Interleukin-17 ligand and receptor family members and the discovery that IL-17 receptor A and IL-17 receptor E form a heteromeric receptor complex that is biologically active, and that IL-17C activity requires the IL-17RA-IL-17RE heteromeric receptor complex. Antagonists of the IL-17RA-IL-17RE heteromeric receptor complex are disclosed, as well as various methods of use.
Claims22
An isolated antibody or fragment thereof that inhibits IL-17RA and IL-17RE from forming an IL-17RA-IL-17RE heteromeric receptor complex.
An isolated antibody or fragment thereof that inhibits activation of the IL-17RA-IL-17RE heteromeric receptor complex.
A method of inhibiting IL-17RA-IL-17RE heteromeric receptor complex formation, comprising exposing a cell expressing IL-17RA, IL-17RE, and IL-17RA-IL-17RE heteromeric receptor complex to an IL-17RA-IL-17RE antagonist such that IL-17RA and IL-17RE are partially or fully inhibited from forming an IL-17RA-IL-17RE heteromeric receptor complex.
A method of inhibiting IL-17RA-IL-17RE heteromeric receptor complex activation, comprising exposing a cell expressing IL-17RA, IL-17RE, and IL-17RA-IL-17RE heteromeric receptor complex to an IL-17RA-IL-17RE antagonist such that IL-17C is partially or fully inhibited from activating said IL-17RA-IL-17RE heteromeric receptor complex.
17-58. (canceled)
A method of treating a disease selected from the group consisting of:
- rheumatoid arthritis, multiple sclerosis, ankylosing spondylitis, psoriatic arthritis, psoriasis, asthma, atopic dermatitis, and chronic obstructive pulmonary disease, comprising administering an IL-17RA-IL-17RE antagonist to a patient in need thereof, wherein said patient's cells express IL-17RA, IL-17RE, and IL-17RA-IL-17RE heteromeric receptor complex, and wherein said antagonist partially or fully inhibits IL-17C from activating said IL-17RA-IL-17RE heteromeric receptor complex.
62-63. (canceled)
A method of treating inflammation and autoimmune disorders in a patient in need thereof, comprising administering to said patient an isolated monoclonal antibody that specifically binds human IL-17RA that inhibits the biological activity of IL-17A, IL-17B, IL-17C, IL-17D, IL-17E (IL-25), IL-17F, and IL-17A/F, wherein the disorders include cartilage inflammation, and/or bone degradation, arthritis, rheumatoid arthritis, juvenile arthritis, juvenile rheumatoid arthritis, pauciarticular juvenile rheumatoid arthritis, polyarticular juvenile rheumatoid arthritis, systemic onset juvenile rheumatoid arthritis, juvenile ankylosing spondylitis, juvenile enteropathic arthritis, juvenile reactive arthritis, juvenile Reter's Syndrome, SEA Syndrome (Seronegativity, Enthesopathy, Arthropathy Syndrome), juvenile dermatomyositis, juvenile psoriatic arthritis, juvenile scleroderma, juvenile systemic lupus erythematosus, juvenile vasculitis, pauciarticular rheumatoid arthritis, polyarticular rheumatoid arthritis, systemic onset rheumatoid arthritis, ankylosing spondylitis, enteropathic arthritis, reactive arthritis, Reter's Syndrome, SEA Syndrome (Seronegativity, Enthesopathy, Arthropathy Syndrome), dermatomyositis, psoriatic arthritis, scleroderma, systemic lupus erythematosus, vasculitis, myolitis, polymyolitis, dermatomyolitis, osteoarthritis, polyarteritis nodossa, Wegener's granulomatosis, arteritis, ploymyalgia rheumatica, sarcoidosis, scleroderma, sclerosis, primary biliary sclerosis, sclerosing cholangitis, Sjogren's syndrome, psoriasis, plaque psoriasis, guttate psoriasis, inverse psoriasis, pustular psoriasis, erythrodermic psoriasis, dermatitis, atopic dermatitis, atherosclerosis, lupus, Still's disease, Systemic Lupus Erythematosus (SLE), myasthenia gravis, multiple sclerosis (MS), asthma, COPD, Guillain-Barre disease, Type I diabetes mellitus, Graves' disease, Addison's disease, Raynaud's phenomenon, autoimmune hepatitis, GVHD, and the like.
Dependencies are inferred from the claim text.